Follow us...

 

Search News Archives

Channels

News

 

 

View Channel

Laboratory Products

 

 

View Channel

Special Offers and Promotions

 

Microscopy | Image Analysis

 

 

View Channel

Separation Science

 

 

View Channel

Coronavirus (COVID-19)

 

 

View Channel

Research & Case Studies

 

 

View Channel

Conferences | Events

Quotient Clinical expands clinical capacity in response to customer adoption of its Synthesis-to-Clinic human ADME service

Quotient ClinicalQuotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), today announced the completion of a major expansion of its clinical facilities in Nottingham, UK. Bed capacity has been increased by 50 per cent and a dedicated sample processing laboratory for human ADME studies has been incorporated. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation.  

The expansion is a direct response to increasing customer adoption of Quotient's Synthesis-to-ClinicTM platform, in particular in support of human ADME studies, and reinforces Quotient's position as a leading provider of 14C-enabled drug development services including Phase 0 microdose, ivMicrotracerTM, and human metabolism studies.

Synthesis-to-Clinic integrates each component required to undertake a 14C-enabled clinical study into a single supply chain, spanning 14C API radiosynthesis through to the clinical study report.  The ability to seamlessly deliver such a program under a single contract, with a single project manager and continuity of scientific input throughout, delivers significant benefits to the drug development project team.

Mark Egerton, MD Quotient Clinical, commented:  "In parallel with the recent expansion of our Pharmaceutical Sciences laboratory and GMP drug product manufacturing facility, the completion of this clinical expansion is another milestone in the development of our business. It underlines the strength of our Synthesis-to-Clinic platform and the benefits it brings to our global client base.  Our expanded facilities will assist the continued development of our services, supporting our customers in taking new and innovative approaches in early drug development."

For more information on Quotient Clinical, please call  UK - +44 (0)115 974 9000; USA -  +1-800-769-3518, email clinical@quotientbioresearch.com or visit www.quotientbioresearch.com/clinical.


If you have not logged into the website then please enter your details below.



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

Today's Picks

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners